Days after classifying one recall for the Alaris infusion pump, the FDA has issued another Class I recall for the device.
On Friday of last week, the FDA issued a Class I recall — the most serious kind — for the BD (NYSE:BDX) Alaris because there is a risk of the keypad lifting up due to fluid entry, an issue that could result in keys that become unresponsive or stuck. BD initiated that recall on March 3, 2021.
Get the full story at our sister site, Drug Delivery Business News.